Only 57.9% of pharmacies in the U.S. stock buprenorphine, a prescription used for medication-assisted treatment (MAT).
That’s according to new research published in JAMA highlighting a potential access issue for patients in substance use disorder (SUD) treatment. The cross-sectional study was based on data from virtual MAT provider Bicycle Health and included responses from 5,283 unique pharmacies across 32 states about their supply of buprenorphine.